OBJECTIVE: The extreme drug resistance (EDR) assay has been correlated with failure of response to chemotherapy in greater than 99% of patients. The goal of this study is to correlate the results of the EDR assay to response to first-line paclitaxel/cisplatin among patients with epithelial ovarian cancer. METHODS: Seventy-five of 100 patients with epithelial ovarian cancer for whom EDR assay was performed were treated with weekly induction cisplatin (1 mg/kg body wt) x 4, followed by monthly paclitaxel (135 mg/m2) and cisplatin (75 mg/m2) x 6 and were evaluable for correlation of response to chemotherapy and EDR assay. Specimens for EDR assay were obtained at primary surgery and the EDR assay was performed by Oncotech, Inc. Response to chemotherapy was correlated to EDR assay results regarding paclitaxel and cisplatin. RESULTS: Among 75 evaluable patients, the prevalence of EDR to paclitaxel was 20.0% (n = 15) and to cisplatin it was 2.7% (n = 2). Only 1 patient (1.3%) exhibited EDR to both paclitaxel and cisplatin. Surgical assessment of response was performed in 42 patients; 33 patients were clinically evaluable. The overall response rate was 85.3%. The overall response rate for patients whose tumors demonstrated no EDR to either paclitaxel or cisplatin did not differ significantly from that for patients whose tumors demonstrated EDR to at least one of these two drugs (86.4% versus 81.3%, respectively, P = 0.692). Similarly, the complete surgical response rate for both groups did not differ significantly (25.4% versus 12.5%, respectively, P = 0. 34). A single patient whose tumor exhibited EDR to both paclitaxel and cisplatin had tumor progression. The sensitivity, specificity, positive predictive value, and negative predictive value of the EDR assay were 79.6, 27.0, 86.0, and 19.0%, respectively. CONCLUSIONS: EDR to paclitaxel does not preclude response to the combination of paclitaxel and cisplatin as primary therapy for patients with epithelial ovarian cancer. The role of the EDR assay in the primary management of patients with epithelial ovarian cancer remains to be determined. Copyright 1998 Academic Press.
OBJECTIVE: The extreme drug resistance (EDR) assay has been correlated with failure of response to chemotherapy in greater than 99% of patients. The goal of this study is to correlate the results of the EDR assay to response to first-line paclitaxel/cisplatin among patients with epithelial ovarian cancer. METHODS: Seventy-five of 100 patients with epithelial ovarian cancer for whom EDR assay was performed were treated with weekly induction cisplatin (1 mg/kg body wt) x 4, followed by monthly paclitaxel (135 mg/m2) and cisplatin (75 mg/m2) x 6 and were evaluable for correlation of response to chemotherapy and EDR assay. Specimens for EDR assay were obtained at primary surgery and the EDR assay was performed by Oncotech, Inc. Response to chemotherapy was correlated to EDR assay results regarding paclitaxel and cisplatin. RESULTS: Among 75 evaluable patients, the prevalence of EDR to paclitaxel was 20.0% (n = 15) and to cisplatin it was 2.7% (n = 2). Only 1 patient (1.3%) exhibited EDR to both paclitaxel and cisplatin. Surgical assessment of response was performed in 42 patients; 33 patients were clinically evaluable. The overall response rate was 85.3%. The overall response rate for patients whose tumors demonstrated no EDR to either paclitaxel or cisplatin did not differ significantly from that for patients whose tumors demonstrated EDR to at least one of these two drugs (86.4% versus 81.3%, respectively, P = 0.692). Similarly, the complete surgical response rate for both groups did not differ significantly (25.4% versus 12.5%, respectively, P = 0. 34). A single patient whose tumor exhibited EDR to both paclitaxel and cisplatin had tumor progression. The sensitivity, specificity, positive predictive value, and negative predictive value of the EDR assay were 79.6, 27.0, 86.0, and 19.0%, respectively. CONCLUSIONS: EDR to paclitaxel does not preclude response to the combination of paclitaxel and cisplatin as primary therapy for patients with epithelial ovarian cancer. The role of the EDR assay in the primary management of patients with epithelial ovarian cancer remains to be determined. Copyright 1998 Academic Press.
Authors: Kentaro Nakayama; Naomi Nakayama; Ben Davidson; Jim J-C Sheu; Natini Jinawath; Antonio Santillan; Ritu Salani; Robert E Bristow; Patrice J Morin; Robert J Kurman; Tian-Li Wang; Ie-Ming Shih Journal: Proc Natl Acad Sci U S A Date: 2006-11-27 Impact factor: 11.205
Authors: Won Deok Joo; Ji Young Lee; Jong Hyeok Kim; Hang Jo Yoo; Hyun Jin Roh; Jeong-Yeol Park; Dae-Yeon Kim; Yong-Man Kim; Young-Tak Kim; Joo-Hyun Nam Journal: J Gynecol Oncol Date: 2009-06-29 Impact factor: 4.401
Authors: Hirohiko Kamiyama; Sherri Rauenzahn; Joong Sup Shim; Collins A Karikari; Georg Feldmann; Li Hua; Mihoko Kamiyama; F William Schuler; Ming-Tseh Lin; Robert M Beaty; Balasubramanyam Karanam; Hong Liang; Michael E Mullendore; Guanglan Mo; Manuel Hidalgo; Elizabeth Jaffee; Ralph H Hruban; H A Jinnah; Richard B S Roden; Antonio Jimeno; Jun O Liu; Anirban Maitra; James R Eshleman Journal: Clin Cancer Res Date: 2013-01-22 Impact factor: 12.531
Authors: Ewa L Gregoraszczuk; Agnieszka Rak-Mardyła; Janusz Ryś; Jerzy Jakubowicz; Krzysztof Urbański Journal: Iran J Pharm Res Date: 2015 Impact factor: 1.696